GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...